Effect	effect	O	O	O	O
of	of	O	O	O	O
adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
combined	combined	O	O	O	O
with	with	O	O	O	O
whole	whole	O	O	O	O
body	body	O	O	O	O
hyperthermia	hyperthermia	O	DISEASE	OTHERS	I
on	on	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
and	and	O	O	O	O
normal	normal	O	O	O	O
tissues	tissues	O	O	O	O
.	.	O	O	O	O

Thermal	thermal	O	O	O	O
enhancement	enhancement	O	O	O	O
of	of	O	O	O	O
Adriamycin-mediated	adriamycin-mediated	O	O	O	O
antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
and	and	O	O	O	O
normal	normal	O	O	O	O
tissue	tissue	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
by	by	O	O	O	O
whole	whole	O	O	O	O
body	body	O	O	O	O
hyperthermia	hyperthermia	O	DISEASE	OTHERS	I
were	were	O	O	O	O
compared	compared	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
F344	f344	O	O	O	O
rat	rat	O	O	O	O
model	model	O	O	O	O
.	.	O	O	O	O

Antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
was	was	O	O	O	O
studied	studied	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
growth	growth	O	O	O	O
delay	delay	O	O	O	O
assay	assay	O	O	O	O
.	.	O	O	O	O

Acute	acute	O	O	O	O
normal	normal	O	O	O	O
tissue	tissue	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
(	(	O	O	O	O
i.e.	i.e.	O	O	O	O
,	,	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
late	late	O	O	O	O
normal	normal	O	O	O	O
tissue	tissue	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
(	(	O	O	O	O
i.e.	i.e.	O	O	O	O
,	,	O	O	O	O
myocardial	myocardial	O	O	O	O
and	and	O	O	O	O
kidney	kidney	O	O	OTHERS	I
injury	injury	O	O	OTHERS	I
)	)	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
by	by	O	O	O	O
functional/physiological	functional/physiological	O	O	O	O
assays	assays	O	O	O	O
and	and	O	O	O	O
by	by	O	O	O	O
morphological	morphological	O	O	O	O
techniques	techniques	O	O	O	O
.	.	O	O	O	O

Whole	whole	O	O	O	O
body	body	O	O	O	O
hyperthermia	hyperthermia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
120	120	O	O	O	O
min	min	O	O	O	O
at	at	O	O	O	O
41.5	41.5	O	O	O	O
degrees	degrees	O	O	O	O
C	c	O	O	OTHERS	I
)	)	O	O	O	O
enhanced	enhanced	O	O	O	O
both	both	O	O	O	O
Adriamycin-mediated	adriamycin-mediated	O	O	O	O
antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
and	and	O	O	O	O
toxic	toxic	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
thermal	thermal	O	O	O	O
enhancement	enhancement	O	O	O	O
ratio	ratio	O	O	O	O
calculated	calculated	O	O	O	O
for	for	O	O	O	O
antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
was	was	O	O	O	O
1.6	1.6	O	O	O	O
.	.	O	O	O	O

Thermal	thermal	O	O	O	O
enhancement	enhancement	O	O	O	O
ratios	ratios	O	O	O	O
estimated	estimated	O	O	O	O
for	for	O	O	O	O
"	"	O	O	O	O
acute	acute	O	O	O	O
"	"	O	O	O	O
hematological	hematological	O	O	O	O
changes	changes	O	O	O	O
were	were	O	O	O	O
1.3	1.3	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
those	those	O	O	O	O
estimated	estimated	O	O	O	O
for	for	O	O	O	O
"	"	O	O	O	O
late	late	O	O	O	O
"	"	O	O	O	O
damage	damage	O	O	O	O
(	(	O	O	O	O
based	based	O	O	O	O
on	on	O	O	O	O
morphological	morphological	O	O	O	O
cardiac	cardiac	O	O	O	O
and	and	O	O	O	O
renal	renal	O	O	OTHERS	I
lesions	lesions	O	O	OTHERS	I
)	)	O	O	O	O
varied	varied	O	O	O	O
between	between	O	O	O	O
2.4	2.4	O	O	O	O
and	and	O	O	O	O
4.3	4.3	O	O	O	O
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
whole	whole	O	O	O	O
body	body	O	O	O	O
hyperthermia	hyperthermia	O	DISEASE	OTHERS	I
enhances	enhances	O	O	O	O
Adriamycin-mediated	adriamycin-mediated	O	O	O	O
antitumor	antitumor	O	O	O	O
effect	effect	O	O	O	O
,	,	O	O	O	O
normal	normal	O	O	O	O
tissue	tissue	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
also	also	O	O	O	O
increased	increased	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
potential	potential	O	O	O	O
therapeutic	therapeutic	O	O	O	O
gain	gain	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
combined	combined	O	O	O	O
modality	modality	O	O	O	O
treatment	treatment	O	O	O	O
is	is	O	O	O	O
eroded	eroded	O	O	O	O
.	.	O	O	O	O

